Clinical trials: Azithromycin
Covid-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
- Trial name
- NCT04348474
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Azidus Brasil
Pneumonia
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients
The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat…
- Trial name
- NCT00643227
- Testing
- clarithromycin extended release (ER), azithromycin SR
- Where
- 72 sites in United States, Argentina and 5 more
- Volunteers
- 504 people
- Sponsor
- Pfizer
Eye Infections, Bacterial
Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers
To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2).
- Trial name
- NCT00357383
- Testing
- Azithromycin (T1225)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Laboratoires Thea
Pharmacokinetics
Drug-Drug Interaction Study of Colchicine and Azithromycin
Azithromycin is a possible weak to moderate inhibitor of CYP3A4, one of the enzymes responsible for the metabolism of colchicine.
- Trial name
- NCT00983294
- Testing
- Colchicine, Azithromycin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Contact Lens Dry Eye
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)
The primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin…
- Trial name
- NCT01105624
- Testing
- azithromycin ophthalmic solution, 1%, Visine® for Contacts®
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Maxillary Sinusitis
Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis
The purpose of this study is to compare compliance between patients with Acute Bacterial Sinusitis (ABS) treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the…
- Trial name
- EASY (NCT01032174)
- Testing
- Azithromycin SR, Amoxiclav 1000 mg
- Volunteers
- 123 people
- Sponsor
- Pfizer
Pre-Bronchiolitis Obliterans Syndrome
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone.
- Trial name
- NCT05654922
- Testing
- ARINA-1, Standard of care only
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Renovion, Inc.
Community-acquired Bacterial Pneumonia
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT02605122
- Testing
- Solithromycin, Standard of Care
- Where
- 58 sites in United States, Bulgaria and 4 more
- Volunteers
- 97 people
- Sponsor
- Melinta Therapeutics, Inc.